Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer.

被引：1
|
作者：
Zurcher, Jean-Philippe
Aedo, Veronica
Stravodimou, Athina
Sarivalasis, Apostolos
Zaman, Khalil
机构：
[1] Univ Hosp CHUV, Dept Oncol, Lausanne, Switzerland
[2] Univ Hosp CHUV, Breast Ctr, Lausanne, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13052
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
    Boyle, Frances
    Beith, Jane
    Burslem, Katie
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    McCarthy, Nicole
    Redfern, Andrew
    Woodward, Natasha
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 3 - 11
  • [32] Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
    Migliaccio, Ilenia
    Leo, Angela
    Galardi, Francesca
    Guarducci, Cristina
    Fusco, Giulio Maria
    Benelli, Matteo
    Di Leo, Angelo
    Biganzoli, Laura
    Malorni, Luca
    CANCERS, 2021, 13 (11)
  • [33] Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study
    Yildirim, E. Caliskan
    Atag, E.
    Yuzugullu, E.
    Unal, O. U.
    Celebi, A.
    Keser, M.
    Uzun, M.
    Keskinkilic, M.
    Simsek, E. Tanrikulu
    Sari, M.
    Yavuzsen, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S378 - S378
  • [34] Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2?-?metastatic or advanced breast cancer patients: a network meta-analysis
    Liu, Yiyuan
    Wu, Jinyao
    Ji, Zeqi
    Chen, Lingzhi
    Zou, Juan
    Zheng, Jiehua
    Lin, Weixun
    Cai, Jiehui
    Chen, Yaokun
    Zheng, Daitian
    Chen, Yexi
    Li, Zhiyang
    BMC CANCER, 2023, 23 (01)
  • [35] Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis
    Yiyuan Liu
    Jinyao Wu
    Zeqi Ji
    Lingzhi Chen
    Juan Zou
    Jiehua Zheng
    Weixun Lin
    Jiehui Cai
    Yaokun Chen
    Daitian Zheng
    Yexi Chen
    Zhiyang Li
    BMC Cancer, 23
  • [36] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    CANCER RESEARCH, 2016, 76
  • [37] Safety and efficacy of concomitant radiation and CDK4/6 inhibitors in breast cancer patients
    Visani, L.
    Ratosa, I.
    Scoccimarro, E.
    Becherini, C.
    Saieva, C.
    Desideri, I.
    Scotti, V.
    Ozarem, M.
    Ribnikar, D.
    Aquilano, M.
    Cerbai, C.
    Orzalesi, L.
    Bernini, M.
    Sanchez, L.
    Nori, J.
    Bianchi, S.
    Meattini, I.
    Livi, L.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S44 - S45
  • [38] Real-world treatment outcomes in patients with HR+HER2-advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy
    Duchnowska, Renata
    Soter, Katarzyna
    Smok-Kalwat, Jolanta
    Grela-Wojewoda, Aleksandra
    Winsko-Szczesnowicz, Karolina
    Pogoda, Katarzyna
    Kade, Grzegorz
    Danielewicz, Iwona
    Szymanowski, Bartosz
    Kiszka, Joanna
    Streb, Joanna
    Kalinka, Ewa
    Lacko, Aleksandra
    Zubrowska, Justyna
    Ziobro, Marek
    Czartoryska-Arlukowicz, Bogumila
    Jurczyk, Michal
    Lewandowski, Tomasz
    Jassem, Jacek
    Bienkowski, Michal
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2-breast cancer: a multicenter real-world data analysis
    Ralser, Damian J.
    Kiver, Verena
    Solomayer, Erich-Franz
    Neeb, Caroline
    Blohmer, Jens-Uwe
    Abramian, Alina V.
    Maass, Nicolai
    Schuetz, Florian
    Kolberg-Liedtke, Cornelia
    Mueller, Carolin
    Rambow, Anna-Christina
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2025, 311 (02) : 423 - 427
  • [40] Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2-Early Breast Cancer
    Klocker, Eva Valentina
    Egle, Daniel
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Gnant, Michael
    DRUGS, 2025, 85 (02) : 149 - 169
12345